<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424670</url>
  </required_header>
  <id_info>
    <org_study_id>242-09-213</org_study_id>
    <nct_id>NCT01424670</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Trial of Delamanid for 6 Months in Patients With Multidrug Resistant Tuberculosis</brief_title>
  <official_title>A Phase 3, Multicenter,Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid Administered Orally as 200 mg Total Daily Dose for Six Months in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine whether delamanid is effective in the treatment of
      Multidrug-resistant Tuberculosis (MDR TB) in combination with other MDR TB medications during
      6 months of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to evaluate the efficacy of delamanid administered orally as 100
      mg twice daily (BID) for 2 months followed by 200 mg once daily (QD) for 4 months in
      combination with an optimized background regimen (OBR) versus placebo with OBR during the
      6-month intensive phase of MDR TB treatment. This trial is a multicenter, randomized,
      double-blind, stratified, placebo-controlled trial conducted globally in 2 parallel groups at
      approximately 18 sites in 7 countries qualified to treat MDR TB. In addition, a subtrial
      comprised of human immunodeficiency virus (HIV) positive patients who will be on
      antiretrovirals (ARVs) during the trial and will be randomized to OBR plus placebo or OBR
      plus delamanid will be conducted sites in South Africa that have been prequalified as having
      an integrated approach to TB and HIV treatment and management and a sufficient population of
      MDR TB patients co-infected with HIV for enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Sputum Culture Conversion</measure>
    <time_frame>6 months</time_frame>
    <description>Distribution of the time to SCC during the 6-months of IMP treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Sputum Culture Converstion</measure>
    <time_frame>6 Months</time_frame>
    <description>Distribution of the time to SCC by 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Outcomes</measure>
    <time_frame>30 months</time_frame>
    <description>Treatment outcomes assessed by principal investigators at the end of treatment with OBR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Culture Conversion</measure>
    <time_frame>2 months</time_frame>
    <description>Proportion of patients with SCC at 2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Culture Conversion</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients with SCC at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Sputum Culture Conversion</measure>
    <time_frame>30 months</time_frame>
    <description>SCC between Month 18 and Month 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome</measure>
    <time_frame>30 Months</time_frame>
    <description>Final outcome at Month 30 as treatment success or failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in TTD</measure>
    <time_frame>30 Months</time_frame>
    <description>Mean change from baseline in time to detection (TTD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean AUC of Change in TTD</measure>
    <time_frame>30 Months</time_frame>
    <description>Mean AUC of change from baseline in time to detection (TTD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Resistance to Delamanid</measure>
    <time_frame>30 Months</time_frame>
    <description>Proportion of patients who develop resistance to delamanid</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in S/S of TB</measure>
    <time_frame>30 Months</time_frame>
    <description>Change in clinical signs and symptoms of TB</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>30 Months</time_frame>
    <description>Proportion of mortality associated with TB</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>30 Months</time_frame>
    <description>Proportion of all-cause mortality in each group</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">511</enrollment>
  <condition>Multidrug Resistant Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delamanid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg BID for 2 months and 200mg QD for 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delamanid</intervention_name>
    <description>100mg BID for 2 months and 200mg QD for 4 months</description>
    <arm_group_label>Delamanid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimized Background Regimen (OBR)</intervention_name>
    <description>• Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country. ARVs will be administered as standard-of-care.</description>
    <arm_group_label>Placebo tablet</arm_group_label>
    <arm_group_label>Delamanid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretrovirals (ARVs)</intervention_name>
    <description>• HIV treatment (i.e. ARVs) will be based on WHO guidelines and recommendations, and in compliance with local/national guidelines for HIV in South Africa (each site). ARVs will be administered as standard-of-care.</description>
    <arm_group_label>Placebo tablet</arm_group_label>
    <arm_group_label>Delamanid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written, informed consent

          -  Current Diagnosis of MDR TB

          -  Chest radiograph consistent with TB

          -  Able to produce sputum

          -  Negative urine pregnancy test and agree to use a highly effective method of birth
             control and/or adequate method of contraception

        Exclusion Criteria:

          -  Allergy to any nitro-imidazoles or nitro-imidazole derivates

          -  Diseases or conditions in which the use of nitro-imidazoles or nitro-imidazole
             derivates is contra-indicated

          -  Use of disallowed medications

          -  Renal impairment

          -  Abnormal ECG

          -  Cardiovascular disorders

          -  BMI &lt; 16 kg/m2

          -  Karnofsky score &lt; 50%

          -  Significant metabolic, gastrointestinal, neurological, psychiatric, or endocrine
             diseases, active malignancy

          -  Alcohol abuse

          -  Pregnant, breast-feeding, or planning to conceive or father a child

          -  Recent use of methadone, benzodiazepines, cocaine, amphetamine/metamphetamine,
             tetrahydrocannabinol, barbiturates, and opiates

          -  Previous exposure to delamanid

          -  Administered an IMP within 1 month prior to Visit 1

          -  Evidence of XDR TB based on the definition from WHO

          -  HIV co-infection for patients screened at sites not participating in the HIV subtrial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajesh Gupta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tartu University Hospital, Lung Clinic</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Agency &quot;Infectology Center of Latvia&quot; Clinic of Tuberculosis and Lung Diseases</name>
      <address>
        <city>Riga</city>
        <zip>LV-2118</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Institution Republican Siauliai Hospital Subsidiary Hospital of Tuberculosis and Lung Diseases</name>
      <address>
        <city>Siauliai</city>
        <zip>LT-76231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases and Tuberculosis Hospital affiliate of Public institution Vilnius University Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-10214</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Medical Sanitary Institution Institute of Phtysiopneumology &quot;Chiril Draganiuc&quot;</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SERVICIO DE NEUMOLOGIA-Hospital Nacional Arzobispo Loayza, Av. 848</name>
      <address>
        <city>Alfonso Ugarte</city>
        <zip>Lima 1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigación Clinica - Servicio de Enfermedades Infecciosas y Tropicales - Hospital Nacional Dos de Mayo. Parque de la Medicina Peruana s/n, cuadra 13 Av. Grau.</name>
      <address>
        <city>Cercado de Lima</city>
        <zip>Lima 1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Enfermedades Neumologicas - Hospital Nacional Sergio E. Bernales, Avenida Tupac Amaru Km 14.5, Urbanizacion Collique</name>
      <address>
        <city>Comas</city>
        <zip>Lima 7</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Hipolito Unanue, Avenida Cesar Vallejo 1390</name>
      <address>
        <city>El Agustino</city>
        <zip>Lima 10</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>De La Salle University (DLSU), Angelo King Medical Research Center, Congressional Avenue</name>
      <address>
        <city>Dasmarinas City</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tropical Disease Foundation, Inc Philippine Institute of Tuberculosis Building. Amorsolo St. cor. Urban Ave., Pio del Pilar</name>
      <address>
        <city>Makati City</city>
        <state>Manila</state>
        <zip>1230</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quezon Institute Compound, E. Rodriquez Avenue</name>
      <address>
        <city>Quezon City</city>
        <state>Metro Manila</state>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research and Development Office, 4th Floor, Room 4010, Lung Center Philippines, Quezon Avenue</name>
      <address>
        <city>Quezon City</city>
        <state>Metro Manila</state>
        <zip>1104</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>THINK, 324 Florida Road</name>
      <address>
        <city>Morningside</city>
        <state>Durban</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TASK Applied Science, Brooklyn Chest Hospital, 1 Stanberry Road, Ysterplaat</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Head of the Department of Internal Medicine, Klerksdorp/Tshepong Hospital, Anderson Street</name>
      <address>
        <city>Klerksdorp</city>
        <zip>2571, NORTH WEST</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Moldova, Republic of</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>South Africa</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <disposition_first_submitted>March 4, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 4, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 25, 2015</disposition_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multidrug resistant tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

